Diarrhoea initiates during the first four weeks of treatment, after which the incidence notably decreases [15,49]
However, tirzepatide has significantly longer half-life than NNC0090-2746 in humans (120 hours vs
Only one in 12 remain on a GLP-1 drug for obesity at three years owenhaskins Jun 26, 2025 2 min read Only 8% of individuals (or one in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from Prime Therapeutics (Prime)
Cortisol peaks in the early morning hours, promoting glucose production
For starters, your brain is about 60% fat, so you need to keep it supplied with good fats
Tirzepatide activates two receptors (GLP-1 and GIP)